|Title:||Peptides as NS3-serine protease inhibitors of hepatitis C virus|
|Abstract:||The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.|
|Inventor(s):||Saksena; Anil K. (Upper Montclair, NJ), Girijavallabhan; Viyyoor Moopil (Parsippany, NJ), Lovey; Raymond G. (West Caldwell, NJ), Jao; Edwin (Warren, NJ), Bennett; Frank (Piscataway, NJ), Mc Cormick; Jinping L. (Edison, NJ), Wang; Haiyan (Cranbury, NJ), Pike; Russell E. (Stanhope, NJ), Bogen; Stephane L. (Somerset, NJ), Chan; Tin-Yau (Edison, NJ), Liu; Yi-Tsung (Morris Township, NJ), Zhu; Zhaoning (East Windsor, NJ), Njoroge; F. George (Warren, NJ), Arasappan; Ashok (Bridgewater, NJ), Parekh; Tejal (Mountain View, CA), Ganguly; Ashit K. (Upper Montclair, NJ), Chen; Kevin X. (Iselin, NJ), Venkatraman; Srikanth (Fords, NJ), Vaccaro; Henry A. (South Plainfield, NJ), Pinto; Patrick A. (Morris Plains, NJ), Santhanam; Bama (Bridgewater, NJ), Kemp; Scott Jeffrey (San Diego, CA), Levy; Odile Esther (San Diego, CA), Lim-Wilby; Marguerita (La Jolla, CA), Tamura; Susan Y. (Santa Fe, NM), Wu; Wanli (Edison, NJ), Hendrata; Siska (Edison, NJ), Huang; Yuhua (Scotch Plains, NJ)|
|Assignee:||Schering Corporation (Kenilworth, NJ) Dendreon Corporation (Seattle, WA)|
Patent Claim Types:|
see list of patent claims
|Compound; Use; Composition;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.